Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...
New research led by NYU Langone Medical Center examines what happens when a patient with multiple sclerosis (MS) who is clinically stable stops taking their medication. The international, multi-site ...
Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...
Healthcare executive and physician brings decades of healthcare leadership, growth, and operational success to scale X Boson next-generation medication optimization services. MENLO PARK, Calif., June ...
Hosted on MSN
Biomarker provides clear criteria for choice of treatment options in multiple sclerosis
Treatment with interferon or with glatiramer acetate? This question arises for many patients who receive a diagnosis of multiple sclerosis (MS) for the first time. Until now, the choice between the ...
Hosted on MSN
Multiple sclerosis medication gap: Study finds women less likely than men to receive drugs
Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results